|
1) Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002; 30: 1288-95
|
|
|
|
2) Savi P, Zachayus JL, Delesque-Touchard N, et al. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A. 2006; 103: 11069-74
|
|
|
|
|
|
3) Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003; 31: 53-9
|
|
|
|
|
|
4) Brandt JT, Close SL, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007; 5: 2429-36
|
|
|
|
|
|
5) Michelson AD, Frelinger AL, 3rd, Braunwald E, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009; 30: 1753-63
|
|
|
|
|
|
6) Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J. 2009; 30: 1744-52
|
|
|
|
|
|
7) Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost. 2008; 6: 1439-41
|
|
|
|
|
|
8) Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol. 2009; 54: 1149-53
|
|
|
|
|
|
9) Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008; 51: 256-60
|
|
|
|
|
|
10) Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010; 363: 1704-14
|
|
|
|
|
|
11) Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009; 360: 753-64
|
|
|
|
|
|
12) Takeuchi F, Kashida M, Okazaki O, et al. Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients. Circ J. 2010; 74: 977-82
|
|
|
|
|
13) Sagrieya H, Berube C, Wen A, et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics. 2010; 20: 407-13
|
|
|
|
|
|
14) Cha PC, Mushiroda T, Takahashi A, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet, in press
|
|
|
|
|
|
15) Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010; 363: 301-4
|
|
|
|
|